Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Mitry

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Journal of Hematology & Oncology|February 25, 2021
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trialRobert J Kreitman, Claire Dearden, Pier Luigi Zinzani, et al.
Oncotarget|February 9, 2018
Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinomaWulfran Cacheux, Virginie Dangles-Marie, Etienne Rouleau, et al.
Lung Cancer (Amsterdam, Netherlands)|November 10, 2019
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancerSai-Hong Ignatius Ou, Shirish M Gadgeel, Fabrice Barlesi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2016
Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patientsThomas Aparicio, Dany Gargot, Laurent Teillet, et al.
Clinics and Research in Hepatology and Gastroenterology|December 14, 2024
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD studyVictoire Dabout, Laurent Mineur, David Tougeron, et al.
The Lancet. Oncology|June 4, 2024
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 studyJean-Luc Van Laethem, Ivan Borbath, Hans Prenen, et al.
British Journal of Cancer|May 25, 2016
Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resectionWulfran Cacheux, Etienne Rouleau, Adrien Briaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal GroupManfred P Lutz, Eric Van Cutsem, Theo Wagener, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2026
Circulating tumor DNA dynamics and clinical outcomes in patients with advanced Colorectal Cancer treated with cetuximab-based induction and maintenance treatmentValérie Boige, Olivier Bouché, Claire Mulot, et al.
JAMA Network Open|September 18, 2023
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialValérie Boige, Hélène Blons, Eric François, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Journal of Hematology & Oncology|February 25, 2021
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trialRobert J Kreitman, Claire Dearden, Pier Luigi Zinzani, et al.
Oncotarget|February 9, 2018
Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinomaWulfran Cacheux, Virginie Dangles-Marie, Etienne Rouleau, et al.
Lung Cancer (Amsterdam, Netherlands)|November 10, 2019
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancerSai-Hong Ignatius Ou, Shirish M Gadgeel, Fabrice Barlesi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2016
Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patientsThomas Aparicio, Dany Gargot, Laurent Teillet, et al.
Clinics and Research in Hepatology and Gastroenterology|December 14, 2024
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD studyVictoire Dabout, Laurent Mineur, David Tougeron, et al.
The Lancet. Oncology|June 4, 2024
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 studyJean-Luc Van Laethem, Ivan Borbath, Hans Prenen, et al.
British Journal of Cancer|May 25, 2016
Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resectionWulfran Cacheux, Etienne Rouleau, Adrien Briaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal GroupManfred P Lutz, Eric Van Cutsem, Theo Wagener, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2026
Circulating tumor DNA dynamics and clinical outcomes in patients with advanced Colorectal Cancer treated with cetuximab-based induction and maintenance treatmentValérie Boige, Olivier Bouché, Claire Mulot, et al.
JAMA Network Open|September 18, 2023
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialValérie Boige, Hélène Blons, Eric François, et al.
Pageof 12